NCT01114438View on ClinicalTrials.gov

Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

July 31, 2013

Conditions
Type 2 DiabetesObesity
Interventions
DEVICE

EndoBarrier Gastrointestinal Liner

EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.

Trial Locations (3)

Unknown

Imperial College/St. Mary's Hospital, London

Trafford General Hospital/NOSC, Manchester

Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
lead

Morphic Medical Inc.

INDUSTRY